The efficacy of the nonselective S1P receptor agonist fingolimod, which was approved by the FDA in 2010 for the treatment of relapsing remitting multiple sclerosis (RRMS), has sparked interest in its clinical evaluation and the addition of additional S1P1 agonists for a growing list of disorders (Crohn’s disease, ulcerative colitis, psoriasis, polymyositis, progressive multiple sclerosis, lupus) [104]. Here, S1PR1 is linked to relapsing-remitting multiple sclerosis.